Salipro Biotech AB

Salipro Biotech AB develops and commercializes the proprietary Salipro® platform, which stabilizes challenging membrane proteins—key drug targets—for use in small molecule and antibody drug discovery. Their technology has enabled structural insights into previously undruggable targets like SLC33A1, relevant to neurodegeneration and cancer. The company operates both internal research programs and numerous collaborations with top-tier pharma/biotech companies to accelerate early-stage therapeutic development targeting difficult membrane proteins such as GPCRs, ion channels, and transporters. Recent partnerships include a major agreement with Boehringer Ingelheim focused on mental health and cardio–renal–metabolic disease programs.